Novocure Secures CE Mark for New Array
Novocure has received CE Mark approval for its new flex array, a polymer-based transducer designed for enhanced delivery of Tumor Treating Fields (TTFields) therapy in glioblastoma patients. The flex array is over 50% thinner and 30% lighter than current models, aiming to improve patient comfort and therapy efficacy. A limited market release in Europe will commence, with insights from initial patient experiences guiding future regulatory filings. This innovation indicates Novocure's commitment to advancing cancer treatment while potentially optimizing treatment outcomes.
- Received CE Mark for the new flex array, indicating regulatory approval.
- Flex array is over 50% thinner and 30% lighter than current commercial arrays, enhancing patient comfort.
- Aimed to optimize Tumor Treating Fields therapy delivery, potentially improving clinical outcomes.
- None.
New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose
ROOT,
“Novocure is committed to improving the patient experience and clinical outcomes through innovation, and the new arrays represent a meaningful milestone reached in our product development journey,” said
With CE Mark for the new arrays, the company will begin a limited market release in
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005113/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
What is the significance of Novocure receiving CE Mark for NVCR's flex array?
How does the new flex array compare to current commercial arrays for NVCR?
When will Novocure's flex array be available in the market?